Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Atara Biotherapeutics, Inc.
< Previous
1
2
3
Next >
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
May 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
February 21, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
February 08, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)
February 08, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
February 06, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 13, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
December 20, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Changes to Its Board of Directors
December 19, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
December 19, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 15, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
December 12, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 02, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
November 23, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate at the Stifel Healthcare Conference
November 09, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
November 08, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
November 01, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022
October 26, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
October 14, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre
September 28, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference
August 31, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update
August 08, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
August 03, 2022
From
Atara Biotherapeutics, Inc.
Via
Business Wire
Tickers
ATRA
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.